Transforming growth factor-b (TGF-b) plays an essential role in regulating the homeostasis of cells in the lymphoid lineage. TGF-b signaling is not required for normal thymopoiesis, but is essential for regulating the expansion, activation, and effector function of the mature CD4 þ and CD8 þ T cells in the peripheral lymphoid organs and target tissues. Recent studies in both mice and humans have elucidated an important and complex role for TGF-b in regulatory T-cell biology. Disruption of TGF-b signaling in T cells impairs the maintenance of regulatory T cells, results in the expansion of activated effector T cells, and is associated with the production of cytokines that have major effects on cells in their environment. While autoimmunity and inflammation are the principal phenotypes associated with the abrogation of TGF-b signaling in T cells in mice, emerging evidence now also directly links Smad-dependent TGF-b signaling in T cells to the suppression of epithelial neoplasia. The TGF-b receptor-activated Smad3 plays a critical role in mediating many of the inhibitory effects of TGF-b signaling in T cells, and has now been established as an important suppressor of leukemogenesis. These studies are increasing our awareness of the many complex mechanisms through which TGF-b signaling controls the pathogenesis of cancer.
Introduction
Consider the many cytokine signaling networks that orchestrate the development and differentiated functions of cells within the hematopoietic, mesenchymal, and epithelial lineages. Classical growth factors, including epidermal growth factor, insulin-like growth factors, and fibroblast growth factors, clearly play essential roles in the epithelial and mesenchymal lineages (Seedorf, 1995; Touw et al., 2000) . In hematopoietic cells, crosstalk between interferons (IFNs), interleukins (IL), and chemokines orchestrates the responses to pathogens and to various antigenic stimuli (Ihle et al., 1995; Williamson and Boswell, 1995; Haque and Williams, 1998; Yasukawa et al., 2000) . However, only transforming growth factor-b (TGF-b) emerges as a bifunctional regulator of the maturation and activity of cells in each of these lineages (Roberts et al., 1985; Kulkarni et al., 2002) , with a dual role in the suppression of carcinogenesis (Piek and Roberts, 2001; Wakefield and Roberts, 2002; Bachman and Park, 2005) . In part, this can be understood if one recognizes or views the principal function of TGF-b signaling to be an arbiter of the response to the many other environmental signals that act on a cell at any given time (Roberts, 1999; Kulkarni et al., 2002; Laouar et al., 2005) .
It is thus not surprising that we have begun to appreciate the important role that TGF-b plays at the interface between inflammation and cancer (MartinsGreen et al., 1994; Coste et al., 1998; Monteleone et al., 2004; Elliott and Blobe, 2005) . The many inhibitory effects of TGF-b on cell cycle progression and cell viability are in a sense predictive of the now well-known tumor suppressor function of this pathway in hematopoietic and epithelial cells (Polyak et al., 1994; Moustakas et al., 2002; Brown et al., 2004; Kaklamani and Pasche, 2004) . The broader influence of TGF-b in the immune system can in part be attributed to the interaction between intermediates in the TGF-b pathway with components downstream of both cytokine receptors and antigen receptors (Jacobsen et al., 1991) , including Toll-like receptors (Moustakas and Heldin, 2003; Xiao et al., 2003) , and modulation of cytokine production Roberts, 1997, 1998; Laouar et al., 2005; Lyakh et al., 2005) . However, the recognition that a disruption or loss of TGF-b signaling within immune cells directly contributes to the initiation and progression of epithelial cancer highlights the role this cytokine plays in controlling cell-to-cell interactions, and the immune surveillance of cancer (Becker et al., , 2005 .
T cells are not unique in their response to TGF-b, but do provide an exquisite example of the ability of TGF-b to influence various stages of development, differentiation, activation, and effector function within a specified lineage . Whether one considers the development of thymic progenitors, the interactions between mature effector T cells and regulatory T cells in the peripheral immune system, or the suppression of their malignant transformation, it is clear that TGF-b signals play an essential role in each. This review is focused on the principal functions of TGF-b in this lineage, starting with effects in thymic progenitor or stem cell populations, and continuing with an examination of essential roles TGF-b intermediates in their mature single-positive CD4
þ and CD8 þ T-cell progeny. A major emphasis will be placed on how loss of TGF-b signaling in T cells contributes to the pathogenesis of cancer, either directly in the T-cell lineage or indirectly in the epithelial compartment. In the end, the evidence should support the concept that the TGF-b signaling pathway has a critical role not only as a specific suppressor of inflammation or cancer but also as a factor that can directly link these two processes, serving as an ideal target for novel preventive strategies aimed at these diseases.
The multiple roles of TGF-b in T-cell biology
The first studies to demonstrate the potential of TGF-b to function as an endogenous regulator of lymphocyte biology were reported within a few years of its discovery (nearly 20 years prior to the writing of this review; Kehrl et al., 1986a, b) . TGF-b was shown to be produced in significant quantities during the activation of naı¨ve T cells and to suppress the T-cell response to IL-2, providing strong evidence for an autocrine TGF-b regulatory loop in T cells. Initial studies in B-lymphocytes demonstrated the loss of TGF-b receptor expression and insensitivity to growth inhibitory effects following infection with Epstein-Barr virus, providing a clue that the transforming potential of viral oncoproteins might be linked to the subversion of TGF-b signaling. Thus, these seminal studies not only emphasized the potential utility of TGF-b as an immune modulator in the treatment of clinical disorders characterized by an excessive or uncontrolled activation of the immune system (Ruscetti and Palladino, 1991) but also provided clues to its role in the suppression of hematopoietic neoplasia (Kim and . The following section examines the role of TGF-b signaling in the T-cell lineage.
TGF-b and T-cell development
Perhaps the strongest evidence that TGF-b is an essential endogenous regulator of T-cell function comes from the very recent advances made through the application of in vivo genetic tests of function Bottinger et al., 1997; Kulkarni et al., 2002) . These include a series of studies in which components of the TGF-b signaling pathway are deleted, either through homologous recombination in stem cells or through conditional strategies for lineagespecific gene targeting (Figure 1 ). In models in which signaling is disrupted at the level of the ligand (TGF-b1) or receptors (TGF-b type I or TGF-b type II), there is ultimately systemic activation of T cells, with spontaneous production of effector cytokines and tissue infiltration, whether the lesion occurs in hematopoietic progenitor or in a T-cell-restricted manner. The basis for this dysregulation in the T lineage has not been clearly defined, but altered thymic development, impaired suppression of T-cell activation, and loss of regulatory T-cell activity have all been proposed.
Several studies have addressed the potential role of TGF-b in regulating thymocytes. In vitro, TGF-b has been shown to oppose the activity of a number of cytokines that regulate thymocyte proliferation and promote survival, including IL-2 and IL-7 (Chantry et al., 1989; Dupuy d'Angeac et al., 1993; Plum et al., 1995) . The addition of TGF-b to fetal thymic organ culture led to a block in differentiation, suppressing the progression of CD44 þ CD25 À with a decrease in the CD44 þ CD25 þ and CD44 À CD25 À precursors (Plum et al., 1995) . The effect of TGF-b on thymocyte development may be linked to the effect of this cytokine on cellular proliferation. Differentiation of CD4 À CD8 lo thymic precursors requires progression through at least one cell division, and this is effectively blocked by TGFb expressed by thymic epithelial cells (Takahama et al., 1994) . Addition of a neutralizing antibody to TGF-b in media conditioned by thymic stromal cells leads to an increase in the percentage of thymocytes entering the S and G2/M phase of the cell cycle (Mukamoto and Kodama, 2000) . These data support the concept that TGF-b, produced by thymic stroma, controls the Similar analyses of cultured human thymocytes have also shown the importance of autocrine TGF-b in the suppression of thymic stem cells or precursor expansion. The proliferation of triple negative (TN) thymocytes expressing CD2 but negative for CD3/TCR as well as CD4 and CD8 is suppressed by autologous CD8 þ T cells, in a manner that can be reversed by the addition of an antibody to neutralized TGF-b activity. However, the CD8 þ T cells were not the source of TGF-b, but instead they served to activate TGF-b produced by the thymic precursors (Mossalayi et al., 1995) . This paradigm in which TGF-b functions as an autocrine inhibitory factor for a stem cell population has also been described for the earliest hematopoietic stem cell population, the CD34 þ lin À uncommitted stem cell. Similar to the thymic precursor, the differentiation and proliferative expansion of the common hematopoietic stem cell are likely under the control of autocrine TGF-b (Jacobsen et al., 1993; Sitnicka et al., 1996) , although mechanisms through which this TGF-b functions in the stem cell microenvironment are not well defined (see articles by Ruscetti and Karlsson, this issue).
In light of these in vitro observations, it is considered somewhat surprising that the thymic phenotypes are relatively normal in mouse models in which genes encoding components of the TGF-b signaling pathway have been disrupted. In newborn Tgf-b1 À/À offspring, thymic cellularity and subset distribution are similar to their wild-type littermates. There is a progressive increase in apoptosis and eventual cortical atrophy in the thymus of Tgf-b1 À/À mice (Chen et al., 2001) , which is likely secondary to the stress effects of systemic inflammation and adrenal corticosteroid production in these mice (Kulkarni et al., 1993; Christ et al., 1994; . These observations may reflect the potential contribution of maternal sources of TGF-b1 to normal thymic development in the newborn . Alternatively, other isoforms within the TGF-b family may compensate for the loss of the type I isoform, as both TGF-b2 and TGF-b3 are produced by thymic epithelial cells. Furthermore, other members of the TGF-b superfamily, including BMP and activin, have been shown to exert similar effects on thymic precursors (Rosendahl et al., 2003) .
To overcome the influence of other sources of TGF-b, conditional gene targeting strategies have been employed to delete genes encoding the TGF-b type II receptor (TbRII) (Leveen et al., 2002; Larsson et al., 2003 Larsson et al., , 2005 . In this system, an inducible deletion of the TbRII gene was effected by the expression of a crerecombinase gene controlled by the IFN-inducible Mx1 promoter (Kuhn et al., 1995) . A lethal inflammatory disease evolved rapidly following induction of the Mx1-driven cre-recombinase, similar to the phenotype observed in the Tgf-b1 À/À mice (Leveen et al., 2002) . Moreover, the phenotype could be transferred to Tgfb1 þ / þ recipient mice, clearly demonstrating the resistance of hematopoietic and immune cells to both autocrine and paracrine sources of TGF-b.
At this point, the exact role for TGF-b in T-cell development remains to be clearly defined. More extensive studies of cells isolated from conditional models, such as those above, will be informative, particularly thymic organ cultures in which combinations of either stroma or thymocytes that are defective in TGF-b signaling are used. The current models involving receptor deletions lead to the complete absence of all TGF-b signals. It is possible that there is a balance between Smad-dependent and -independent pathways that might be important and only uncovered by studies in which these downstream intermediates are specifically targeted. Germline disruption of the SMAD3 gene is not associated with a defect in thymopoiesis. We have completed preliminary studies of mice in which the genes encoding the receptor-activated Smad2 and the common intermediate, Smad4, and thus far find no overt difference in thymic development. These models will be very useful for the analysis of how these signaling pathways regulate stromal-thymocyte interactions and the response of thymic cells to stress, cytokines. The current data might be interpreted to suggest that TGF-b signaling is not essential to normal thymic development. However, it remains highly likely that the differentiation and proliferative expansion of thymic progenitors into their mature CD4 þ and CD8 þ T-cell subsets are each regulated by this pathway in a context-dependent manner.
TGF-b signaling in the differentiation of T-lymphocytes
TGF-b has the ability to influence the differentiation of cells from multiple lineages, including cells within both the epithelial and hematopoietic compartments. Not surprisingly, many of the mechanisms underlying the effects of TGF-b on stem cell populations are important in the response to TGF-b in the maturation and function of their progeny. As discussed above, one of the most prominent effects of TGF-b on the committed lymphoid progenitors is to suppress their proliferative capacity. In vivo, this involves multiple mechanisms, which include the suppression of cytokines like IL-2 (D' Angeac et al., 1991; McKarns and Kaminski, 2000) , IL-6 (Baroni et al., 2003) , and IL-7 (Tang et al., 1997) , each of which exert important effects on lymphocyte proliferation and viability. There is extensive crosstalk between intermediates in the TGF-b pathway and downstream targets of the receptors for these cytokines Ebert, 1999; Ohta et al., 2000; Huang et al., 2002; Wierenga et al., 2002; Baroni et al., 2003; Zhang et al., 2004) . The Jak-Stat pathway of signal transducers acts downstream of receptors for the ILs and IFNs, and activation of the Jak-Stat cascade has, most commonly, a suppressive effect on TGF-b signaling (Ulloa et al., 1999; Eickelberg et al., 2001) . For example, IFN-g signaling through Jak-Stat can suppress Smad-dependent TGF-b signaling through upregulation of the inhibitory Smad7. Similarly, protein inhibitors of activated Stat3 (PIAS3) can augment Smad signaling. However, these effects can be context dependent and there are reports of Jak-Stat signaling augmenting the TGF-b response. For example, IL-6 has been shown to modulate TGF-b receptor compartmentalization and trafficking, effectively increasing the partition of TbRII within the nonlipid raft fraction (Zhang et al., 2005) . In addition, protein inhibitors of activated Stat signaling (PIASY) have also been found to impair TGF-b signaling, through a ligand-dependent interaction with the receptor-activated Smad3 (Long et al., 2003) . TGF-b has also been shown to suppress Jak-Stat signaling via mechanisms such as the induction of the suppressor of cytokine signaling (SOCS3) (Fox et al., 2003) , but the ability of TGF-b to suppress activation of the Jak-Stat cascade has been somewhat controversial (Bright and Sriram, 1998; Sudarshan et al., 1999) . Here again, it is important to remember that the effects of TGF-b on converging signaling cascades are often both dose-and context dependent. The bidirectional effects of TGF-b in hematopoietic stem cells have been linked to a strong induction of Smad3 phosphorylation at the high inhibitory concentrations, with concomitant activation of stress-related transcription factors, and to a Smad3-independent activation of STAT signaling at low, stimulatory concentrations (Kale and Vaidya, 2004) . This crosstalk between lymphokine receptor signaling and TGF-b signaling pathways partly explains the context-dependent effects of TGF-b in the immune system, and also suggests mechanisms mediating the antagonistic effects of these factors in lymphoid neoplasia (Iwamoto et al., 2002) .
The context-dependent effects of TGF-b are also highlighted by the complicated nature through which this cytokine regulates the differentiation of naı¨ve CD4 þ T cells. The acquisition of a mature T helper type 1 (T H 1) or T helper type 2 (T H 2) phenotype is largely defined by the cytokines produced by these subsets (T H 1 producing IFN-g, IL-2, and IL-12; T H 2 producing primarily IL-4, and also IL-5 and IL-13). TGF-b has been shown to block the acquisition of both T H 1 and T H 2 phenotypes through mechanisms that include the suppression of events downstream of the T-cell receptor. This includes an ability to inhibit phosphorylation of the Tek kinase Itk, and the subsequent rise in intracellular calcium and activation of the MAPK cascade . In vivo models largely support a major role for TGF-b in suppressing the development of a T H 1 response. There is prominent production of IFN-g and other proinflammatory cytokines in Tgf-b1 À/À mice and in mice with conditional deletion of the TGF-b receptors, specifically in the hematopoietic progenitor pool. However, a knockdown of TGF-b signaling through the expression of the dominant-negative acting TbRII in T cells leads to elaboration of both T H 1 and T H 2 cytokines, in some instances by the same cell (Gorelik and Flavell, 2000) . In the latter model, mice exhibit an increase in circulating IgA, which likely reflects an increased T-cell production of cytokines, particularly IL-5 and IL-6, which have important roles in B-cell homeostasis and in immunoglobulin gene switch to IgA (Figure 2) .
Several factors are known to induce the development of T H 1 cells, particularly IFN-g and IL-12. TGF-b can directly suppress IL-12-dependent T H 1 differentiation through mechanisms that may include both the suppression of the transcription factor Tbet, a master regulator of Th1 gene expression Lin et al., 2005) , and the downregulation of IL-12 responsiveness (Gorham et al., 1998; Pardoux et al., 1999) . However, the development of IL-12-independent differentiation toward T H 1 is actually enhanced by TGF-b (Smeltz et al., 2005) , an observation that again reveals the context-dependent activity of TGF-b, and also provides a note of caution regarding the application of TGF-b to augment the production of T cells with a regulatory phenotype (see below).
In vivo, the influence of TGF-b on the evolution of a T H 1-type immune response is not only a function of the direct effects that this cytokine exerts on the T cell but also a consequence of the effects that it exerts on natural killer (NK) cells, dendritic cells (DCs), and stromal cells involved in T-cell education. In a recent study, a complimentary set of murine models was developed, each using a dominant-negative acting TbRII receptor expressed directly either in NK cells or in DCs, to address the role of TGF-b in this complex process (Laouar et al., 2005) . By utilizing a CD11c promoter, the authors could sustain reasonable expression of the dominant-negative acting TbRII receptor in both DCs and in NK cells. While blockade of TGF-b signaling had no effect on DC production of IL-12, there was a significant expansion of NK cells secreting large amounts of IFN-g. The model that emerges from these studies suggests that TGF-b impairs cell-mediated immunity in vivo through the suppression of the IL-12-stimulated production of IFN-g by NK cells. However, other studies have also pointed to significant effects of TGF-b on DC function. In humans with multiple Phenotypes associated with these models reflect the increased production of both T H 1 and T H 2 cytokines, including IL-5 and IL-6. The production of these cytokines has been linked to hyperplasia in target populations, including plasma cells and mucosal epithelial, and implicate the T cell as having a role in mediating the suppression of epithelial and plasma cell neoplasia myeloma, production of TGF-b by the plasma cell neoplasia significantly impairs the upregulation of B7 costimulatory molecules, including CD80 and CD86. As one would predict, exposure of cultured DCs to a neutralizing anti-TGF-b antibody will correct this defect, as will exposure to either IFN-g or IL-12. Taken together, these data define multiple mechanisms through which TGF-b signals control the development of a T H 1 response through the modulation of T cells and their communication with environmental signals in a manner that is context dependent.
TGF-b and the regulatory T cell
TGF-b has been widely viewed as playing an important role in the biology of regulatory T cells, which have broadly been defined by their capacity to suppress immune responses, and each have been implicated in the induction of oral tolerance (Miller et al., 1992) , suppression of autoimmune disease (Chrobak, 2003) , susceptibility to infection (Garba et al., 2002; Kullberg et al., 2002; Monteleone et al., 2004) , and cancerassociated immunosuppression (Fu et al., 2000) . Various T-cell subsets, including CD4 þ , CD8 þ , and NK cells, have been shown to exert suppressor activity in different contexts, but it is the naturally occurring CD4 þ CD25 þ T cell that has emerged as the most well characterized (Shevach et al., 2001) , and there has been an intense focus on the role of TGF-b in their development (Yamagiwa et al., 2001; Wan and Flavell, 2005) , maintenance (Marie et al., 2005) , and effector function (Piccirillo et al., 2002) (Figure 3 ). Although the importance of TGF-b signaling in the CD4 þ CD25 þ regulatory T cell has often been controversial, this likely reflects the existence of distinct populations of regulatory cells that express these markers and variables that influence their function in the context of diverse immune pathologies in vivo.
Studies conducted in the Tgf-b1 À/À mouse model suggest that this cytokine is not required for the development of the naturally occurring CD4 þ CD25 þ regulatory T cell . CD4 þ CD25 þ regulatory T cells are present in the thymus and periphery of neonatal Tgf-b1 À/À mice, and they display the normal surface characteristics described for these cells, including the expression of cytotoxic T-lymphocyte (CTL)A4 and GITR, and they are anergic. In vitro, these Tgf-b1 À/À CD4 þ CD25 þ regulatory T cells are equivalent to wild-type Treg in their capacity to suppress effector T-cell proliferation (Piccirillo et al., 2002) . The suggestion that TGF-b might be important in the development of CD4 þ CD25 þ regulatory T cells was based partly on the observation that the addition of exogenous TGF-b to cultures of CD4 þ CD25 À T cells could induce the expression of Foxp3 Park et al., 2004) , a transcription factor required for the development of this specialized class of regulatory cells (Khattri et al., 2001) . More recent studies in the Tgf-b1
À/À mouse model have shown that levels of Foxp3 are normal in the thymic CD4 þ CD25 þ precursors for regulatory T cells, but found that these levels decline in peripheral CD4 þ CD25 þ regulatory T cells (Marie et al., 2005) . These data suggest that there is a significant contribution of both autocrine and paracrine sources of TGF-b1 to the maintenance and function of
þ Treg cells partially suppress autoimmune pathology when used in an adoptive transfer model in which the recipient is Tgf-b1 þ / þ , and can also suppress Tgf-b1 (Fahlen et al., 2005) . One interpretation of these observations is that TGF-b1 produced by other cells within the environment of the Treg can sustain their suppressor phenotype and activity. Indeed, the in vivo suppression of CD4 þ CD45 RBhi -induced colitis is abrogated when a neutralizing anti-TGF-b antibody is administered together with the Tgf-b1
þ Treg induces expression of TGF-b1 by nearby stromathymal and mesenchymal cells, and the pathogenic effector T cells may actually be the relevant producer of this cytokine. Taken together, these data indicate that TGF-b is not required for the development of the thymic precursor for CD4 þ CD25 þ regulatory T cells, but that it does have a role for the maintenance of this class of regulatory cells in the periphery, and that this can be attributed to an ability to control the expression of Foxp3. 
TGF-b signaling in T cells JJ Letterio
Perhaps more controversial is the role of TGF-b as an effector of the suppressor function of the CD4 þ CD25 þ regulatory T cell. At a very superficial level, it would seem intuitive that a soluble, secreted factor like TGF-b would not be an effector of suppression for a class of regulatory cells that act through a contact-dependent mechanism. One model proposed that retention of TGF-b on the plasma membrane would serve as a mechanism through which TGF-b can act in a contactdependent manner (Nakamura et al., 2001) . This argument was supported by in vitro experiments in which TGF-b antagonists (neutralizing antibodies, latency-associated peptide, or TGF-b-soluble type II receptor) reversed suppression. However, the reversal of in vitro suppression by these antagonists has not been observed in every setting, and is contradicted by the observation that Tgf-b1
þ Treg cells are equivalent to wild-type Treg in vitro. However, in vitro suppression is compromised when Tgf-b1
þ Treg cells are combined with Tgf-b1
APCs, an observation that is consistent with a requirement for either autocrine or paracrine TGF-b1 to maintain Foxp3 expression and sustain the suppressor phenotype (Marie et al., 2005) .
TGF-b, T cells, and the suppression of epithelial neoplasia
The identification of mutations and deletions in genes encoding components of the TGF-b receptors and downstream signaling intermediates have clearly established the tumor suppressor activity of this pathway (Markowitz and de Caestecker et al., 2000; Downing, 2004; Elliott and Blobe, 2005) . The mechanisms mediating the effects of TGF-b on cell cycle progression, apoptosis, and differentiation are principally involved in the suppression of tumorigenesis by TGF-b. However, these same activities are also operative on T cells, NK cells, antigen-presenting cells (APCs), and other components of cellular immunity, presenting the great paradox that this potent tumor suppressor also effectively promotes tumorigenesis by subverting all the elements that are central to the development of antitumor immunity. The concept that TGF-b can impair the development and activity of CTLs is well established and has placed TGF-b at the interface between T cells and epithelial carcinogenesis (Herrmann and Abdi, 1996; Beck et al., 2001) . TGF-b can act directly on CTLs, inhibiting their generation and activity, or indirectly, by induction of regulatory or suppressor T cells that act in an antigen-nonspecific manner to suppress immunity. However, more recent studies are shedding light on mechanisms through which T-cell resistance to TGF-b can promote epithelial carcinogenesis. These studies provide further evidence of the context-dependent effects of TGF-b signaling in disease pathogenesis, and create a new paradigm linking inflammation and cancer. The section that follows will highlight studies that have demonstrated the direct effects of TGF-b on CTLs, and mechanisms involved.
We will also consider recent studies that have linked T-cell resistance to TGF-b to an increased susceptibility to epithelial cancer.
TGF-b signaling in T cells and tumor immunity
The first studies of TGF-b in tumor-induced immunosuppression were focused on the suppression of CTL induction and activity, largely due to the initial recognition that TGF-b acts to suppress production of IL-2 and to inhibit activation in response to a number of stimuli. However, as our understanding of the mechanisms mediating induction of tumor immunity has evolved, so has the view regarding the role of TGF-b in this process. While the suppression of tumor-specific CTL remains a target for TGF-b activity, the regulatory T cell is now viewed as a critical intermediate in this process and as a major target for the effects of TGF-b in disease pathogenesis. The role of TGF-b in regulatory T cells has been discussed in the preceding section, so the following will focus on some of the specific data that have implicated TGF-b in the direct modulation of CTLs.
The earliest studies examined the effects of adding TGF-b to ex vivo-cultured mouse splenocytes or human peripheral blood lymphocytes. In most instances, TGFb did not inhibit the effector function of LAK cells or of allo-specific CTL when added directly to the short-term cytolytic assays (Mule et al., 1988) , an observation that has consistently been reproduced in different experimental models. Other studies focused on the generation of LAK cells and allo-specific CTL in vitro demonstrated that TGF-b had profound inhibitory effects, and suggested that this inhibition may be an indirect result of suppressed cytokine production as well as a direct antiproliferative effect on CTL (Mule et al., 1988; Inge et al., 1992) . These data were supported by studies which indicated that TGF-b-producing tumor cells failed to stimulate primary CTL responses in vitro and were not effective in vivo for directly stimulating primary CTL or in priming for CTL responses despite retaining expression for class I major histocompatibility complex molecules and the tumor-specific antigen (TorreAmione et al., 1990) .
The latter studies imply a direct effect of TGF-b on priming of CTL by tumors or by APCs. A recent report addressed this question by evaluating DC/tumor fusion vaccines generated with either a non-TGF-b-secreting mouse colon cancer cell line (CT26) or a paired TGF-bsecreting stable cell line (generated using a retroviral vector expressing TGF-b; Kao et al., 2003) . The DC/ CT26-TGF-b fusion cells failed to induce a strong T-cell proliferative response in vitro, mainly due to the effect of TGF-b on T-cell responsiveness rather than DC stimulatory capability. In vivo, animals vaccinated with DC/CT26-TGF-b fusion vaccine had lower tumorspecific CTL activity and diminished survival following tumor challenge when compared with animals immunized with a control DC/CT26-neohybrid vaccine. Ex vivo exposure of DCs to TGF-b did not appear to lessen the efficacy of DC vaccine. These data are consistent with the concept that the priming of T cells by DCs or tumor cells can be negatively influenced by TGF-b in the microenvironment, and argue strongly that systemic neutralization of TGF-b will greatly enhance the effectiveness of cancer immunotherapy.
Other in vivo studies on models of tumor-induced immunosuppression have strengthened the concept that tumor production of TGF-b was a principal mechanism mediating suppression. BALB/c mice bearing the plasmacytoma MOPC-315 fail to generate tumorspecific CTL and have increased plasma TGF-b levels and activity in ascites fluid. Induction of tumor-specific CTL following low-dose melphalan therapy in MOPC-315 tumor-bearing mice is associated with a reduction in TGF-b production that may have enabled the development of tumor-eradicating immunity (Weiskirch et al., 1994) . Similarly, ascites collected from BALB/c mice bearing MH134 hepatoma cells suppress the generation of CTL responses to TNP and alloantigens in vitro, and the suppression of CD4 þ Th function required for anti-TNP CTL responses was almost completely prevented by the addition of anti-TGF-b antibody to cultures (Tada et al., 1991) .
These results indicate that TGF-b produced by tumor cells induces deleterious effects specifically on the CD4 þ Th subset. To assess the specific role of T cells subsets in TGF-b-induced immunosuppression, more recent studies have disrupted TGF-b signaling specifically in either CD4 þ or CD8 þ T cells through the use of transgenic expression of radically truncated dominantnegative acting TGF-b type II receptor (DN-TbRII). As predicted, T-cell-specific blockade of TGF-b signaling allows the generation of an immune response capable of eradicating tumors in mice challenged with live tumor cells (Gorelik and Flavell, 2001 ). CD4 þ and CD8 þ T cells expressing the DN-TbRII were isolated from the transgenic animals and mixed with normal CD4 þ and CD8 þ T cells from syngeneic controls and used to reconstitute T-cell subsets in T-cell-deficient recipients of the same tumor cell lines. In this adoptive transfer study, resistance to TGF-b in the CD4 þ T cells had no effect on the ability to generate CTL and tumor immunity, but loss of a response in CD8 þ T cells abrogates the antitumor immune response. While these results clearly implicate CD8
þ T cells as a key target of TGF-b, they do not definitely exclude the involvement of CD4 þ T cells in TGF-b-induced suppression. Transgenic expression of a DN-TbRII is in most instances a 'knockdown' of signaling, and may not completely impair all response to TGF-b, such that the influence of TGF-b on gene expression may remain intact, despite the loss of effects of TGF-b on cell growth.
Other studies have highlighted the influence of cytokines on the induction or response to TGF-b in the suppression of CTL-mediated tumor immunity. For example, in a canine transmissible venereal tumor (CTVT), which produces TGF-b1, the CTVT tumor cells stop expressing MHC molecules during the progression phase, but their expression is restored during the regression phase. TGF-b1 secreted by CTVT cells clearly suppressed LAK cytotoxicity. However, tumor-infiltrating lymphocytes isolated from regressing CTVT secreted high concentrations of IL-6, which was shown to antagonize the anti-LAK activity of tumor cell-derived TGF-b1. In another BALB/c tumor model (15-12RM), cytotoxic T-lymphocyte (CTL)-mediated tumor immunosurveillance is suppressed by a CD1d-restricted lymphocyte, most likely a NK T cell, which produces IL-13. However, suppression was not a result of a direct effect of IL-13 on the CTL, but rather via IL-13-induced expression of TGF-b1 by a myeloid population defined by CD11b/Gr1 expression (Terabe et al., 2003) . Thus, the mechanisms by which TGF-b impairs tumor immunity are complex and clearly involve communication between CTL and other contributors to cellular immunity.
Smad-dependent signaling in T cells controlling mucosal inflammation and cancer
The involvement of Smad-dependent and -independent pathways on CTL generation has not been defined. However, genetically engineered mouse models in which genes encoding Smad proteins have uncovered important Smad-dependent signaling in T-cell regulation, mucosoal immunity, and epithelial carcinogenesis in the gastrointestinal tract. Mutational inactivation of the SMAD3 gene in embryonic stem cells is not associated with embryonic lethality, but does result in specific T-cell defects in the adult mouse. Three distinct models in which the SMAD3 gene is deleted have been described (Zhu et al., 1998; Datto et al., 1999; Yang et al., 1999) . Analysis in two of these models revealed important roles for Smad3 in mediating the inhibitory effects of TGF-b on the activation and proliferation of T cells (Datto et al., 1999; Yang et al., 1999) , on IL-2 production, chemotaxis and wound healing (Ashcroft et al., 1999; Ashcroft and Roberts, 2000) , and other disorders (Roberts et al., 2003) . Although SMAD3 À/À mice appear normal at birth, they invariably develop inflammation within the mucosal surfaces, with localized abscesses at many sites, including periorbital and periodontal regions . There is an accumulation of activated T cells within the mucosa, and production of cytokines by these T cells may underlie some of the observed pathology.
Mutations in the MADH3 gene have not been associated with human intestinal tumorigenesis, and the lack of a role for Smad3 in intestinal neoplasia is supported by the phenotypes of two distinct SMAD3 mutants produced by two different laboratories. However, while these mutations yielded identical phenotypes, a third SMAD3 mouse mutant is distinguished by the development of a metastatic colon cancer, with 100% frequency on a pure SV129 background (Zhu et al., 1998) . The importance of genetic background and potential differences in enteric microbial flora might contribute to these disparities. This particular mutation has also been combined with a disruption in the gene encoding p27 Kip1 , an inhibitor of cyclin-dependent kinases (Philipp-Staheli et al., 2002) . While the authors did observe spontaneous intestinal tumors in this study, they found no evidence for metastatic spread of the SMAD3 À/À colon carcinomas, and failed to see any cooperation between Smad3 and p27
Kip1 in the suppression of intestinal neoplasia. These tumors continue to express APC, suggesting that inactivation of the b-catenin/APC pathway is not involved, and there was no evidence to suggest loss of heterozygosity for SMAD3 or tumorigenesis in the SMAD3 þ /À mice. The absence of mutations in the MADH3 gene in humans does not obviate a role for Smad3-dependent signaling in intestinal neoplasia. This receptor-activated intermediate has been found to be a target of oncoproteins in leukemia (see below) and Smad3 activity may be suppressed via induction of the inhibitory Smad7. For example, activated TGF-b1 is abundant in the mucosa of controls and Helicobacter pylori-infected patients, with no significant difference between the two groups . Despite this, in whole biopsy specimens and isolated mucosal cells from H. pylori-infected patients, there was defective TGF-b1-associated Smad3 phosphorylation, which was associated with a high expression of the inhibitor Smad7. Blocking Smad7 with antisense oligonucleotides restored TGF-b1 signaling in biopsy specimens from H. pylori-infected patients and concomitantly reduced IFN-g and T-bet. T H 1 cytokines, such as IFN-g, induce the expression of Smad7, which ultimately prevents endogenous TGF-b1 from downregulating the T H 1 response, and clearly links inflammation to TGF-b and the suppression of epithelial neoplasia. Indeed, the suppression of inflammation may be the primary mechanism through which Smad3 signaling acts to suppress epithelial cancer, as the loss of Smad3 is conversely linked to a reduction in the rate of chemically induced carcinogenesis in the skin (Li et al., 2004) , where inflammation may not be a key factor in the initiation or progression.
Disruption of the expression of the SMAD4 gene in mice has yielded a valuable model that clearly validates the relevance of Smad4-dependent signal transduction in the suppression of colon carcinogenesis. Taketo and Takaku have shown that as SMAD4 heterozygote mice (SMAD4 þ /À ) age, these mice develop multiple polyps within the stomach and duodenum (Takaku et al., 1998) . These polyps have abundant stroma and eosinophilic infiltrates, features that are also true of the human juvenile polyposis syndrome, in kindreds that carry germline mutations in the SMAD4 gene. More importantly, loss of heterozygosity for the SMAD4 gene occurred in 100% of polyps of 18-month-old heterozygotes, indicating LOH for SMAD4 as an early event in polyp formation. Perhaps not surprisingly, there is now experimental evidence that a disruption in Smad4-dependent signaling in T cells might contribute to this phenotype. In a model developed in our laboratory, the conditional deletion of the SMAD4 gene specifically in T cells leads to a progressive intestinal epithelial hyperplasia (unpublished). We observe a significant increase in T-cell production of IL-6 in vivo and in vitro in this model, consistent with the transgenic model in which T-cell resistance to TGF-b is induced by a CD2-driven dnTbRII (Becker et al., , 2005 . More importantly, we also see a significant production of IL-5, a key factor in the induction, activation, and migration of eosinophils. We are currently utilizing this model to explore the role of Smad-4-dependent signaling in T cells and the contribution that it makes to the suppression of gastrointestinal tumorigenesis.
SMAD signaling and the leukemic stem cell
Studies in freshly isolated primary leukemic cells or established cell lines have consistently demonstrated the acquisition of TGF-b resistance as a phenotype associated with leukemic transformation. TGF-b is perhaps the most potent endogenous inhibitor of hematopoietic stem and progenitor cell proliferation, and effectively opposes the activities of most cytokines that promote their expansion and survival. It would follow logically that subversion of the TGF-b pathway would be a common event in the leukemic stem cell, and recent progress has identified novel mechanisms and a specific role for Smad3 in the suppression of leukemogenesis (Figure 4) .
The case for TGF-b signaling in the suppression of lymphoid neoplasia
In human lymphoid malignancies, mutations in genes encoding the TGF-b receptors have been reported and loss of cell surface expression of TGF-b receptors has been described in both T and B lymphoid tumors (reviewed in Kim and . In mice, expression of a kinase-defective TbRII in T cells under the Figure 4 Smad3-dependent signaling in the suppression of leukemogenesis. The gene encoding Smad3 MADH3 has not been found to be mutated in human cancer, but has been identified as a putative target of a number of oncoproteins expressed in both myeloid and lymphoid leukemias. Gene targeting studies in mice have been used to validate the hypothesis that loss of Smad3-dependent signaling cooperates with oncogenic mutations that are involved in the induction of leukemia control of the CD2 promoter results in a progressive lymphoproliferative process characterized by diffuse vasculitis and expansion of CD8 þ T cells in the peripheral lymphoid tissue (Lucas et al., 2000) . These T cells develop abnormal ploidy and evolve into a leukemia/lymphoma-like syndrome that is responsible for early mortality within 3-4 months of age (Lucas et al., 2004) . Multiple chromosomal abnormalities were observed in these leukemias, including aneuploidy, deletions, and translocations, although few of these changes occurred in more than one tumor. These data suggest a significant role for TGF-b in the inhibition of the proliferative expansion or growth of memory-or antigen-experienced T cells. Recent data suggest that crosstalk between IL-15 and TGF-b signaling pathways has a significant role in maintaining homeostasis in this T-cell subset (Campbell et al., 2001) . Alterations in the TGF-b signaling pathway that impair the ability of TGF-b to oppose either prosurvival or mitogenic effects of cytokines such as IL-7 and IL-15 would create the potential for rapid growth, and allow for the expansion of a clonal population harboring an oncogenic or growth-favoring mutation.
More recently, TGF-bRII gene has been conditionally deleted in the hematopoietic stem cell through the approach of conditional gene targeting (Leveen et al., 2002) . In this model, mice develop a rapidly fatal automimmune disease that is identical in most aspects to the syndrome that evolves in Tgf-b1 À/À mice. In each instance, the loss of receptor or ligand is complete, and thus one could argue that the more slowly progressive syndromes in the T-cell-specific dnTbRII mice may be due to a persistence of some level of TGF-b signaling, and this could conceivably involve Smad-independent MAPK-, PI3K-or S6-kinase-related pathways (Attisano and Wrana, 2002; Shi and Massague, 2003) . Nevertheless, the collective data from these and other preclinical models support the concept that this pathway functions to suppress tumorigenesis in the T-cell lineage.
A specific role for SMAD3 in leukemogenesis
Until recently, the evaluation of TGF-b resistance in human lymphoid malignancies has mostly focused on assessments of the TGF-b receptor genes and their expression. However, a role for Smad-dependent signaling in the suppression of leukemogenesis has now been demonstrated in both myeloid and lymphoid leukemias. While mutations in the human MADH4 gene have been described in acute myeloid leukemia (AML), mutations in genes encoding the receptor-activated Smads have not been described. However, it is now clear that epigenetic mechanisms that impair either the function or expression of Smad3 protein are important in the process of leukemogenesis. In AML, the novel protein products produced by transcripts of the fusion genes generated by chromosomal translocations have been shown to interact physically with Smad3 and suppress Smad3-dependent transcriptional responses to TGF-b. Examples include the AML/ETO, an AML/Evi oncoprotein, each of which inhibit the ability of TGF-b to block proliferation (Kurokawa et al., 1998; Sood et al., 1999) . The viral oncoprotein, Tax, has also been implicated in the suppression of the Smad3-dependent effects of TGFb. We have recently reviewed these studies elsewhere (Kim and Letterio, 2003) .
More recently, an analysis of another oncoprotein, the PML-RARb oncoprotein of acute promyelocytic leukemia (APL), has revealed an important role for the tumor suppressor of acute promyelocytic leukemia (PML) as an essential mediator of TGF-b signaling (Lin et al., 2004; Fuchs et al., 2005) . Lin and colleagues show that the expression of cytoplasmic Pml is induced by TGF-b. More importantly, they demonstrate for the first time that cytoplasmic PML physically interacts with Smad2/3 and with SARA (Smad anchor for receptor activation) and provide evidence that this interaction is required for their assembly and trafficking with the TGF-b receptor in the early endosome. They also demonstrate that PML-RARa oncoprotein of APL can antagonize cytoplasmic PML function and provide evidence that APL cells and Pml-null cells have similar defects in TGF-b signaling, again implicating the receptor-activated Smad3 as a principal target of a leukemogenic oncoprotein.
Our laboratory has focused on the potential role of Smad3 as a suppressor of leukemogenesis in the lymphoid lineage. As noted above, it had been suggested in the literature that the Smad3 protein might be a relevant target of the Tax oncoprotein of adult T-cell leukemia. Our studies in the SMAD3 À/À mouse model had revealed a requirement for Smad3 in mediating the inhibitory effects of TGF-b on the proliferation of T cells, so we studied the role of Smad3 in human T-cell leukemogenesis. We identified the specific loss of Smad3 protein as a unique feature of pediatric T-cell acute lymphoblastic leukemia (T ALL) (Downing, 2004; Wolfraim et al., 2004) . Despite normal levels of SMAD3 messenger RNA, no Smad3 protein was detected in leukemic cells from children with T-cell ALL, while Smad3 remained readily detectable in pre-B ALL specimens. Smad2 was readily detected in all extracts of leukemic cells. In mice, we found that a reduction in the level of Smad3 impairs the responses of T cells to TGF-b, and thus the suppression by TGF-b of T-cell production of IL-2 and of the mitogenic response to T-cell receptor ligation is diminished in the Smad3 heterozygote (SMAD3 þ /À ). The loss of Smad3 alone was insufficient to induce leukemia. However, leukemia develops in Smad3-deficient mice when coupled with the loss of the p27 Kip1 , a cyclindependent kinase inhibitor whose gene is frequently altered in human T-cell ALL. These data suggest that TGF-b participates in suppression of leukemogenesis, potentially by suppressing the proliferative expansion of lymphocytes through a Smad3-dependent mechanism. Loss of Smad3 expression may cooperate more generally with alterations in the retinoblastoma protein pathway, and studies aimed at identifying cooperating oncogenic events represent an important focus for future studies.
Conclusions
There is a long-held view that inflammation and cancer are linked, both mechanistically and in their pathogenesis. New data from in vivo genetic tests of function clearly support this concept and are providing new perspectives for how alterations in pathways that control cellular immunity participate in the process of carcinogenesis. The topics covered in this review illustrate the complexity with which the TGF-b ligands and components of the TGF-b signaling pathway act to regulate steps throughout the development and maturation of cells within the T lineage. The data show that, in one context, TGF-b signaling in T cells can act to suppress the progression of epithelial cancers, in part through regulating the APC-T cell interaction during CTL generation. However, in other contexts, it is the loss of TGF-b signaling in T cells that may directly promote epithelial cancer, by leading to unregulated production of cytokines that act directly on the epithelial cell. Smad-dependent signaling plays a prominent role in mediating these effects and in the suppression of the leukemic stem cell. Knowledge gained from these preclinical studies predict that both agonists and antagonists of the TGF-b pathway will be important additions to our therapeutic armamentarium, but their application will require careful analysis of the risks and potential benefits in each setting in which they are applied.
